Drug Shortage Report for CINQAIR
| Report ID | 114421 |
| Drug Identification Number | 02456419 |
| Brand name | CINQAIR |
| Common or Proper name | CINQAIR(RESLIZUMAB)IV INJ 100MG/10ML |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | RESLIZUMAB |
| Strength(s) | 10MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1 10ml |
| ATC code | R03DX |
| ATC description | OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-05-07 |
| Estimated end date | 2020-10-31 |
| Actual end date | 2020-09-02 |
| Shortage status | Resolved |
| Updated date | 2020-09-03 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v10 | 2020-09-03 | French | Compare |
| v9 | 2020-09-03 | English | Compare |
| v8 | 2020-07-16 | French | Compare |
| v7 | 2020-07-16 | English | Compare |
| v6 | 2020-07-09 | French | Compare |
| v5 | 2020-07-09 | English | Compare |
| v4 | 2020-06-25 | French | Compare |
| v3 | 2020-06-25 | English | Compare |
| v2 | 2020-05-08 | French | Compare |
| v1 | 2020-05-08 | English | Compare |
Showing 1 to 10 of 10